Resimmune clinical trials
Also written A-dmDT390-bisFv(UCHT1).
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses resimmune is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses resimmune is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis FungoidesWithdrawnPhase 2Virogen Biotechnology Inc.NCT02943642Written as A-dmDT390-bisFv(UCHT1)
- A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV MelanomaStatus unknownPhase 1/2Angimmune LLCNCT02990416Written as A-dmDT390-bisFv(UCHT1)
- A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)CompletedPhase 2Angimmune LLCNCT00611208Written as A-dmDT390-bisFv(UCHT1)
- A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV MelanomaTerminatedPhase 1/2Angimmune LLCNCT01888081Written as A-dmDT390-bisFv(UCHT1) (Resimmune®)
Codes
What other systems call resimmune · ClinicalTrials.gg INT017553
- UNII (FDA) P7MQ9ZOQ82RESIMMUNEOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P7MQ9ZOQ82 | RESIMMUNE | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.